RBRC10042

Information1

Image
BRC No.RBRC10042
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.Cg-Mapt<tm1.1(MAPT)Tcs> App<tm2(NL-F)Tcs>
Former Common name
H-2 Haplotype
ES Cell line
Background strain
Appearance
Strain development
Strain description
Colony maintenance
ReferencesJ. Biol. Chem., 294(34):12754-12765 (2019). 31273083
Nat. Commun., 10(1):2394 (2019). 31160584

Health Report

Examination Date / Room / Rack2020/02/17Room:3-ARack:I
2019/12/16Room:3-ARack:I
2019/10/21Room:3-ARack:I
2019/08/26Room:3-ARack:I
2019/06/17Room:3-ARack:I

Gene

Gene info
Gene symbolGene nameChr.Allele symbolAllele namePromoter
Maptmicrotubule-associated protein tau11Mapt<tm1.1(MAPT)Tcs>targeted mutation 1.1, Takaomi C. Saido

Gene symbolGene nameChr.Allele symbolAllele namePromoter
Frtyeast FRT (flippase recombination target) site11Frt

Gene symbolGene nameChr.Allele symbolAllele namePromoter
MAPTmicrotubule-associated protein tau (human)11MAPT

Gene symbolGene nameChr.Allele symbolAllele namePromoter
loxPphage P1 loxP11loxP

Gene symbolGene nameChr.Allele symbolAllele namePromoter
Appamyloid beta (A4) precursor protein16App<tm2(NL-F)Tcs>targeted mutation 2, Takaomi C. Saido

Gene symbolGene nameChr.Allele symbolAllele namePromoter
Frtyeast FRT (flippase recombination target) site16Frt

Gene symbolGene nameChr.Allele symbolAllele namePromoter
loxPphage P1 loxP16loxP

Information2

Donor DNAhuman MAPT genomic DNA, yeast FRT site, Phage P1 loxP site, mouse Mapt genomic DNA, phage P1 loxP site, yeast FRT (flipase recombination target) site, mouse App genomic DNA (mutant type)
Research applicationCre/loxP system
FLP/frt system
Specific Term and ConditionsPrior to requesting the BIOLOGICAL RESOURCE, the RECIPIENT must obtain approval from the DEPOSITOR using the Approval Form. The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research.
RIKEN BRC does not provide any for-profit organization with the BIOLOGICAL RESOURCE. For-profit organizations must contact the DEPOSITOR (saido@brain.riken.jp) for a licensing contract.
1. Definitions
The following definitions shall apply to this Agreement:
Material: BIOLOGICAL RESOURCE, Progeny and Unmodified Derivatives. Material shall not include (i)Modifications, or (ii) other substances created by RECIPIENT through the use of Material which are not Progeny or Unmodified Derivatives.
Progeny: Unmodified descendant from Material, such as virus from virus, cell from cell, or organism from organism.
Unmodified Derivatives: Substances created by RECIPIENT which constitute an unmodified functional subunit or product expressed by the BIOLOGICAL RESOURCE. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the BIOLOGICAL RESOURCE, proteins expressed by DNA/RNA supplied by DEPOSITOR,or monoclonal antibodies secreted by a hybridoma cell line, subsets of the BIOLOGICAL RESOURCE such as novel plasmids or vectors.
Modifications: a) Substances created by RECIPIENT which contain/incorporate Material (BIOLOGICAL RESOURCE, Progeny or Unmodified Derivatives) or b) gene manipulated materials which are created through genome editing using Material.
2. Report
RECIPIENT shall supply DEPOSITOR with a written report about all research results related to Material as outlined in the Research Plan.
3. Publications
RECIPIENT will have the right to publish and disclose the results of the research. RECIPIENT shall submit the intended publication to DEPOSITOR at least thirty (30) days prior to the submission of the abstracts and manuscripts. DEPOSITOR may within this 30-day period request RECIPIENT, in writing, to delete any reference to DEPOSITOR's CONFIDENTIAL INFORMATION (as defined blow). RECIPIENT agrees to acknowledge Hiroki Sasaguri, Shoko HASHIMOTO, Takashi SAITO, and Takaomi C. SAIDO, according to generally accepted authorship attributions, as co-authors in the first domestic oral presentation, first international oral presentation, and first written international publication as related to Material unless otherwise requested by the DEPOSITOR. Thereafter, RECIPIENT agrees to acknowledge Hiroki Sasaguri, Shoko HASHIMOTO, Takashi SAITO, and Takaomi C. SAIDO in an “acknowledgement” section, and does not need to co-author Hiroki Sasaguri, Shoko HASHIMOTO, Takashi SAITO, and Takaomi C. SAIDO. RECIPIENT also agrees to cite the original publications [Saito et al., Nature Neuroscience 17, 661-663 (2014), Sasaguri et al., EMBO J 36, 2473-2487 (2017), Hashimoto et al., Nature Communications 10, 2394 (2019) and Saito et al., Journal of Biological Chemistry 294(34) 12754-12765 (2019)] in all publications obtained using Material. RECIPIENT agrees to acknowledge DEPOSITOR in all oral presentations and written publications as related to Material.
4. Confidential Information
RECIPIENT shall keep confidential any or all information marked "CONFIDENTIAL" that is received from DEPOSITOR and related to Material including oral discussions if they are reduced to writing within thirty (30) days and are marked "CONFIDENTIAL" (collectively as "CONFIDENTIAL INFORMATION"). RECIPIENT shall not use CONFIDENTIAL INFORMATION for any purpose other than the Research Plan.
5. Ownership
DEPOSITOR retains ownership of Material, including any Material contained or incorporated in Modifications. Notwithstanding anything to the contrary herein, RECIPIENT agrees that DEPOSITOR retains ownership of the following: (1) any Progeny created as a result of breeding of Material(female) and Material(male); and (2) any Progeny created as a result of backcrossing of Material and non-artificially-modified mouse. If RECIPIENT Scientist intends to crossbreed Material with any other proprietary mouse, RECIPIENT Scientist shall notify DEPOSITOR Scientist in writing. RECIPIENT acknowledges that it may cause any dispute with regards to ownership of Progeny, therefore RECIPIENT shall not proceed such plan before DEPOSITOR and RECIPIENT reach an agreement regarding ownership of such Progeny. If RECIPIENT Scientist intends to a) incorporate any proprietary biological or chemical materials into Material or b) perform genome editing using Material, RECIPIENT shall warrant it will not affect DEPOSITOR's ownership of Material created as a result of such research. Joint ownership of Modifications between DEPOSITOR and RECIPIENT may be negotiated if RECIPIENT notifies DEPOSITOR in writing prior to such research. In any case, RECIPIENT shall bear maintenance costs of Progeny above and Material which are at RECIPIENT site.
6. Invention
If any invention is conceived and reduced to practice by RECIPIENT in the performance of the Research Plan involving Material, RECIPIENT agrees to promptly inform the invention to DEPOSITOR. DEPOSITOR and RECIPIENT will consult each other to determine inventorship and ownership of the invention based on the respective Party's contribution to the invention, before filing an application for a patent. In the case of a jointly owned application, the Parties will separately enter into a joint application agreement including the sharing of ownership, patent costs and licensing income, as well as the responsible Party for the application procedures etc.
7. Contractor
Notwithstanding foregoing, if approved by DEPOSITOR, RECIPIENT can, only to the extent necessary to the research described within this Agreement, contract out breeding and storage of Material to a third party ("Contractor"). In such cases, RECIPIENT shall have Contractor use Material only for the contracted services, not sell, transfer or distribute Material without the prior written consent of DEPOSITOR, and comply with all terms and conditions of this Agreement. RECIPIENT shall assume all liabilities in connection with the receipt, handling, storage, and use of Materials at Contractor. In no event shall DEPOSITOR be liable for any loss, claim, damage or liability, of whatsoever kind of nature, which may rise from or in connection with the transportation of Material from DEPOSITOR to Contractor or from Contractor to RECIPIENT. RECIPIENT shall promptly inform DEPOSITOR of the particulars of Contractor including its name, address and phone number.
DepositorTakaomi C. Saido (RIKEN)
Strain Statusan icon for Frozen embryosFrozen embryos
an icon for Frozen spermFrozen sperm
Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
Cryopreserved sperm (within 1 month)
Cryopreserved embryos (within 1 month)
Additional Info.MTA(English), APPROVAL FORM(English)
Lab HP (Japanese)

BRC mice in Publications

No Data